Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
By Michelle Arkin, J. Wells. 2004
1,568 citations recorded by the source corpus.
Subfields: Molecular Biology, Organic Chemistry, Computational Chemistry & Drug Discovery
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Alexandre M. J. J. Bonvin
- Shengyou Huang
- Xiaoqin Zou
- Brian G. Pierce
- Jeffrey J. Gray
- Zhiping Weng
- Yang Zhang
- Juan Fernández-Recio
In Organic Chemistry
- Shengyou Huang
- Xiaoqin Zou
- Sarel Jacob Fleishman
- Glaucius Oliva
- Ryan G. Coleman
- Paramjit S. Arora
- David Baker
- Adriano Defini Andricopulo
In Computational Chemistry & Drug Discovery
- Shengyou Huang
- Xiaoqin Zou
- Jeffrey J. Gray
- L. Ferreira
- Glaucius Oliva
- Ricardo N Dos Santos
- Adriano Defini Andricopulo
- Hahnbeom Park
Citations in the corpus
- Molecular Docking and Structure-Based Drug Design Strategies (2015, background): “Many diseases, such as cancer, can be attributed to defective protein-protein interactions (PPIs); therefore, this type of intermolecular event is a highly attractive target in drug discovery [115].”
- A decade and a half of protein intrinsic disorder: Biology still waits for physics (2013, background): “In addition to nutlins inhibiting p53-Mdm2 interaction, several other small molecules also act by blocking protein– protein interactions.(272,273) Some of these interactions involve one structured partner and one disordered partner, with disordered segments becoming a-helix”
- Recent progress and future directions in protein-protein docking. (2008, neutral): “1389-2037/08 $55.00+.00 © 2008 Bentham Science Publishers Ltd. Keywords: Protein-protein docking, protein-protein interactions, docking algorithms, data-driven docking, molecular dynamics, protein structure databases, protein interface prediction, CAPRI.”
- Systematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors (2010, background): “We propose that receptors with binding clefts are candidates for high-throughput screening efforts with small molecule libraries currently available to chemical biologists.(1,33) It is expected that several of these targets would not be of interest for inhibitor design owing to their biological func”